- Q1 net sales reached $270.7 million, up 8.1% year over year
- Net earnings increased to $40.3 million, with adjusted EBITDA of $74.3 million
- Animal Nutrition & Health sales grew 8.6% to $62.2 million
- Growth driven by both monogastric and ruminant markets
- Strong cash flow generation, with $33.8 million in free cash flow
Balchem Corporation reported record financial performance for the first quarter of 2026, with growth in sales, earnings, and profitability across all business segments.
Total net sales reached $270.7 million, representing an 8.1% increase year over year, while net earnings rose to $40.3 million. Adjusted EBITDA increased 12.1% to $74.3 million, reflecting improved operating performance and favorable product mix.
Animal Nutrition Growth
The company’s Animal Nutrition and Health segment generated $62.2 million in sales, up 8.6% compared to the prior year. Growth was driven by increased demand across both monogastric and ruminant markets.
Segment earnings also improved, supported by higher sales volumes, though partially offset by increased input costs and operating expenses.
Broad-Based Performance
Balchem reported growth across all three business segments, with leadership highlighting the company’s resilience amid global market uncertainty. Strong operating cash flow of $40.1 million and free cash flow of $33.8 million further supported the quarter’s performance.
The company indicated confidence in continued growth, citing ongoing strategic initiatives and stable demand across its portfolio.
Information sourced from company press release.
